Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

Core Insights - Adial Pharmaceuticals has announced the publication of an international patent application for its lead investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in heavy drinking patients, with patent protection expected to last until at least 2045 [1][2] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with AD04 being a genetically targeted serotonin-3 receptor antagonist [3] - The company is planning a new Phase 3 clinical trial program for AUD, utilizing a proprietary diagnostic genetic test to identify target genotypes [3] Clinical Development - The ONWARD trial for AD04 has shown promising results in reducing drinking among heavy drinking patients, with no significant safety or tolerability concerns reported [3] - AD04 is also believed to have potential applications in treating other addictive disorders, including Opioid Use Disorder, gambling, and obesity [3]